Skip to Content

Vera Therapeutics Inc Class A VERA

Morningstar Rating
$35.89 +0.23 (0.65%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VERA is trading within a range we consider fairly valued.
Price
$35.25
Fair Value
$378.83
Uncertainty
Extreme
1-Star Price
$6,434.69
5-Star Price
$3.13
Economic Moat
Zvvg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$35.66
Day Range
$34.3836.08
52-Week Range
$9.2450.78
Bid/Ask
$35.89 / $38.50
Market Cap
$1.96 Bil
Volume/Avg
1.9 Mil / 922,338

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
55

Comparables

Valuation

Metric
VERA
ERAS
ALLK
Price/Earnings (Normalized)
Price/Book Value
5.551.110.95
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
VERA
ERAS
ALLK
Quick Ratio
27.879.843.88
Current Ratio
28.6310.144.11
Interest Coverage
−20.76
Quick Ratio
VERA
ERAS
ALLK

Profitability

Metric
VERA
ERAS
ALLK
Return on Assets (Normalized)
−35.75%−24.04%−54.70%
Return on Equity (Normalized)
−47.90%−29.71%−73.03%
Return on Invested Capital (Normalized)
−41.21%−29.69%−64.58%
Return on Assets
VERA
ERAS
ALLK
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
TljrwjhdqBtpm$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
CqgzpvpYhdffrg$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
FwgszmwgQvjnm$116.1 Bil
Moderna Inc
MRNA
RzjbqckjsZctw$51.1 Bil
argenx SE ADR
ARGX
HrflgnpFpn$22.9 Bil
Alnylam Pharmaceuticals Inc
ALNY
VwwrzhsNjbby$21.0 Bil
BioNTech SE ADR
BNTX
PjwwscpqfXbgx$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
DsszrsggRbjyjzn$15.9 Bil
United Therapeutics Corp
UTHR
TlwtqpmDkv$14.0 Bil
Incyte Corp
INCY
VcqfvvxrFfrqt$12.5 Bil

Sponsor Center